Zentalis Pharmaceuticals Inc [ZNTL] stock prices are up 1.50% to $1.35 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling.
From an analyst’s perspective:
Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] stock has seen the most recent analyst activity on August 12, 2024, when Wedbush upgraded its rating to a Neutral but kept the price target unchanged to $4 for it. Previously, UBS downgraded its rating to Neutral on June 20, 2024, and dropped its price target to $5. On June 18, 2024, downgrade downgraded it’s rating to Equal Weight. Wedbush downgraded its rating to an Underperform and decreased its price target to $4 on June 18, 2024. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $8 on June 18, 2024. Jefferies downgraded its rating to Hold for this stock on June 18, 2024, and downed its price target to $6. In a note dated November 08, 2023, Wedbush downgraded a Neutral rating on this stock and revised its target price from $38 to $12.
The stock price of Zentalis Pharmaceuticals Inc [ZNTL] has been fluctuating between $1.01 and $3.33 over the past year. Currently, Wall Street analysts expect the stock to reach $2 within the next 12 months. Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] shares were valued at $1.35 at the most recent close of the market. An investor can expect a potential return of 48.15% based on the average ZNTL price forecast.
Analyzing the ZNTL fundamentals
Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -6.81%, Pretax Profit Margin comes in at -6.07%, and Net Profit Margin reading is -6.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.52 and Total Capital is -0.59. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3217 points at the first support level, and at 1.2933 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3667, and for the 2nd resistance point, it is at 1.3833.
Ratios To Look Out For
It’s worth pointing out that Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL]’s Current Ratio is 7.76. Further, the Quick Ratio stands at 7.76, while the Cash Ratio is 0.96. Considering the valuation of this stock, the price to sales ratio is 3.63, the price to book ratio is 0.39.
Transactions by insiders
Recent insider trading involved Matrix Capital Management Comp, 10% Owner, that happened on Dec 15 ’25 when 7.5 million shares were sold. Director, Myers Scott Dunseth completed a deal on Apr 30 ’25 to buy 21000.0 shares. Meanwhile, Chief Medical Officer Bruns Ingmar bought 20000.0 shares on Feb 06 ’25.
